NCT06844032Recruiting
Predictors of Poor Prognosis in HFpEF
Clinical, Hemodynamic and Neurohumoral Predictors of Poor Prognosis in Heart Failure With Preserved Ejection Fraction
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 19 Feb 2025
- Start date
- 31 Jan 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Diseases
- Heart failure
- NCT number
- NCT06844032
What you commit to
- Study type: Observational
- Planned participants: 500
- From 31 Jan 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exacerbation of heart failure less than 3 months prior to study entry.
Other illness
- Evidence of myocardial ischemia during stress echocardiography;
- Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);
- Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;
- Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy);
- Primary pulmonary artery hypertension;
- Significant left-sided structural valve disease;
- Non-cardiac conditions that complicate/exclude participation in the study;
Lab values
- Anemia (Hb \< 100 g/L);
- Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (CKD-EPI);
Other
- Significant lesions of the main coronary arteries;
Who the study is looking for
- Signed and data informed consent;
- New York Heart Association (NYHA) class II-III heart failure;
- Left ventricular ejection fraction \> 50%;
- Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADEMICIAN E.I.CHAZOV. of the Ministry of Health of the Russian Federation Coordinator of this site? Confirm its status | Moscow | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.